EMMI Eyes IPO: Soaring Profits, but Overly Dependent on Government?
Jakarta - PT Esa Medika Mandiri Tbk (EMMI) is preparing to list on the Indonesia Stock Exchange (BEI) through an Initial Public Offering (IPO) scheme. The company, which operates in the wholesale trade of laboratory, pharmaceutical, and medical equipment, is aiming to raise fresh funds to strengthen its capital structure and support working capital. Below is an in-depth review of EMMI’s prospectus, covering financial performance trends, operational ratios, and an analysis of positive catalysts as well as the company’s business risks.
Based on prospectus data, EMMI recorded a solid year-on-year (YoY) financial performance growth trend. The significant increase in revenue in 2024 and 2025 was primarily driven by the acquisition of large-scale procurement contracts financed by international donor agencies.
In terms of revenue structure, EMMI has a very massive exposure to government projects. Sales realisation in 2025 was almost entirely sourced from state health agency tenders, while the portion of sales to the non-government segment was relatively minimal. Although the prospectus does not detail the historical revenue portion by product type, the focus of EMMI’s business lines can be clearly mapped through the allocation of IPO funds for working capital for inventory purchases. The company is allocating approximately IDR 165 billion specifically to secure stock of critical medical device products. Electro Cauters and various surgical instruments are the most dominant portfolio being prepared to meet the demand of healthcare facilities.
Through this corporate action, the company is targeting maximum fund raising of IDR 269.27 billion. The majority of the IPO proceeds will be allocated for working capital needs and the settlement of part of its bank debt obligations.
As the lead underwriter, PT BRI Danareksa Sekuritas has a fairly varied portfolio in guiding issuers to list on the exchange. Based on the history of several recent IPOs it has handled, the majority of share price movements on the first day of trading opening recorded positive results, although some recorded slight weakness due to market dynamics.
EMMI’s overall financial metrics show consistent improvement from year to year. The company’s ability to generate net operating profit against sales surged to a level of 7.14% in 2025. In terms of solvency, the debt-to-equity ratio (DER) was massively reduced from a position of 5.08x in 2023 to 2.89x in 2025. On the other hand, the Interest Coverage Ratio (ICR) rose to a level of 2.47x, indicating a healthier capacity to cover interest expenses, although the Current Ratio (0.92x) still requires short-term liquidity strengthening to meet bank covenant requirements.
The sustainability prospects of EMMI’s business are supported by the company’s track record in securing contracts from international-scale institutions. In addition to acting as an exclusive distributor, EMMI is beginning to develop a consumable goods business segment through the manufacture of surgical sutures in cooperation with a global entity. This strategic initiative is expected to strengthen recurring income sources in the future.
From a risk profile perspective, investors need to scrutinise the revenue structure concentrated on the government segment. This condition places the company’s cash flow in a position vulnerable to adjustments in the State Budget (APBN) allocation. Coupled with the fact that the majority of E-Catalogue procurement sales are not based on long-term contracts, the stability of EMMI’s revenue has the potential to experience fluctuations.